Shane D. Walton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shane D. Walton has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Jonathan P. Davis
11 shared publicationsBin Liu
Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH
6 shared publicationsJalal K. Siddiqui
Department of Physiology and Cell Biology, The Ohio State University Columbus, OH, USA
6 shared publicationsBrandon J. Biesiadecki
Department of Physiology and Cell Biology and the Davis Heart and Lung Research Institute, The Ohio State University Columbus, OH, USA
4 shared publications- Brandon J. Biesiadecki
The Department of Physiology and Cell Biology and the Davis Heart and Lung Research Institute, The Ohio State University, 333 W. 10th Ave., Columbus, OH, 43210, USA
4 shared publications Elizabeth A. Brundage
4 shared publications
Latest Publications
- Open Access
- 1 February 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (5) , 1554-1567
Converter domain mutations in myosin alter structural kinetics and motor function
- 1 February 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (5) , 1554-1567
Open AccessConverter domain mutations in myosin alter structural kinetics and motor function
- Open Access
- 15 May 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (10)
Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin‐Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia
Background: Catecholaminergic polymorphic ventricular tachycardia ( CPVT ) is a familial arrhythmogenic syndrome characterized by sudden death. There are several genetic forms of CPVT associated with mutations in genes encoding the cardiac ryanodine receptor (RyR2) and its auxiliary proteins including calsequestrin ( CASQ 2) and calmodulin (CaM). It has been suggested that impairment of the ability of RyR2 to stay closed (ie, refractory) during diastole may be a common mechanism for these diseases. Here, we explore the possibility of engineering CaM variants that normalize abbreviated RyR2 refractoriness for subsequent viral‐mediated delivery to alleviate arrhythmias in non–CaM‐related CPVT . Methods and Results: To that end, we have designed a CaM protein ( GSH ‐M37Q; dubbed as therapeutic CaM or T‐CaM) that exhibited a slowed N‐terminal Ca dissociation rate and prolonged RyR2 refractoriness in permeabilized myocytes derived from CPVT mice carrying the CASQ 2 mutation R33Q. This T‐CaM was introduced to the heart of R33Q mice through recombinant adeno‐associated viral vector serotype 9. Eight weeks postinfection, we performed confocal microscopy to assess Ca handling and recorded surface ECGs to assess susceptibility to arrhythmias in vivo. During catecholamine stimulation with isoproterenol, T‐CaM reduced isoproterenol‐promoted diastolic Ca waves in isolated CPVT cardiomyocytes. Importantly, T‐CaM exposure abolished ventricular tachycardia in CPVT mice challenged with catecholamines. Conclusions: Our results suggest that gene transfer of T‐CaM by adeno‐associated viral vector serotype 9 improves myocyte Ca handling and alleviates arrhythmias in a calsequestrin‐associated CPVT model, thus supporting the potential of a CaM‐based antiarrhythmic approach as a therapeutic avenue for genetically distinct forms of CPVT .
- 15 May 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (10)
Open AccessGene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin‐Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia
Background: Catecholaminergic polymorphic ventricular tachycardia ( CPVT ) is a familial arrhythmogenic syndrome characterized by sudden death. There are several genetic forms of CPVT associated with mutations in genes encoding the cardiac ryanodine receptor (RyR2) and its auxiliary proteins including calsequestrin ( CASQ 2) and calmodulin (CaM). It has been suggested that impairment of the ability of RyR2 to stay closed (ie, refractory) during diastole may be a common mechanism for these diseases. Here, we explore the possibility of engineering CaM variants that normalize abbreviated RyR2 refractoriness for subsequent viral‐mediated delivery to alleviate arrhythmias in non–CaM‐related CPVT . Methods and Results: To that end, we have designed a CaM protein ( GSH ‐M37Q; dubbed as therapeutic CaM or T‐CaM) that exhibited a slowed N‐terminal Ca dissociation rate and prolonged RyR2 refractoriness in permeabilized myocytes derived from CPVT mice carrying the CASQ 2 mutation R33Q. This T‐CaM was introduced to the heart of R33Q mice through recombinant adeno‐associated viral vector serotype 9. Eight weeks postinfection, we performed confocal microscopy to assess Ca handling and recorded surface ECGs to assess susceptibility to arrhythmias in vivo. During catecholamine stimulation with isoproterenol, T‐CaM reduced isoproterenol‐promoted diastolic Ca waves in isolated CPVT cardiomyocytes. Importantly, T‐CaM exposure abolished ventricular tachycardia in CPVT mice challenged with catecholamines. Conclusions: Our results suggest that gene transfer of T‐CaM by adeno‐associated viral vector serotype 9 improves myocyte Ca handling and alleviates arrhythmias in a calsequestrin‐associated CPVT model, thus supporting the potential of a CaM‐based antiarrhythmic approach as a therapeutic avenue for genetically distinct forms of CPVT .
- Open Access
- 1 February 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (3) , 321a-321A
Mutations in the Converter Domain of Myosin V Demonstrate Coupling Between Lever Arm Swing and Phosphate Release
- 1 February 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (3) , 321a-321A
Open AccessMutations in the Converter Domain of Myosin V Demonstrate Coupling Between Lever Arm Swing and Phosphate Release
- Open Access
- 15 February 2017
- Published by Frontiers Media SA in Frontiers in Plant Science
- Vol. 08, 208
Divergent Soybean Calmodulins Respond Similarly to Calcium Transients: Insight into Differential Target Regulation
Plants commonly respond to stressors by modulating the expression of a large family of calcium binding proteins including isoforms of the ubiquitous signaling protein calmodulin (CaM). The various plant CaM isoforms are thought to differentially regulate the activity of specific target proteins to modulate cellular stress responses. The mechanism(s) behind differential target activation by the plant CaMs is unknown. In this study, we used steady-state and stopped-flow fluorescence spectroscopy to investigate the strategy by which two soybean CaMs (sCaM1 and sCaM4) have evolved to differentially regulate NAD kinase (NADK), which is activated by sCaM1 but inhibited by sCaM4. Although the isolated proteins have different cation binding properties, in the presence of Mg²⁺ and the CaM binding domains from proteins that are differentially regulated, the two plant CaMs respond nearly identically to rapid and slow Ca²⁺ transients. Our data suggest that the plant CaMs have evolved to bind certain targets with comparable affinities, respond similarly to a particular Ca²⁺ signature, but achieve different structural states, only one of which can activate the enzyme. Understanding the basis for differential enzyme regulation by the plant CaMs is the first step to engineering a vertebrate CaM that will selectively alter the CaM signaling network.
- 15 February 2017
- Published by Frontiers Media SA in Frontiers in Plant Science
- Vol. 08, 208
Open AccessDivergent Soybean Calmodulins Respond Similarly to Calcium Transients: Insight into Differential Target Regulation
Plants commonly respond to stressors by modulating the expression of a large family of calcium binding proteins including isoforms of the ubiquitous signaling protein calmodulin (CaM). The various plant CaM isoforms are thought to differentially regulate the activity of specific target proteins to modulate cellular stress responses. The mechanism(s) behind differential target activation by the plant CaMs is unknown. In this study, we used steady-state and stopped-flow fluorescence spectroscopy to investigate the strategy by which two soybean CaMs (sCaM1 and sCaM4) have evolved to differentially regulate NAD kinase (NADK), which is activated by sCaM1 but inhibited by sCaM4. Although the isolated proteins have different cation binding properties, in the presence of Mg²⁺ and the CaM binding domains from proteins that are differentially regulated, the two plant CaMs respond nearly identically to rapid and slow Ca²⁺ transients. Our data suggest that the plant CaMs have evolved to bind certain targets with comparable affinities, respond similarly to a particular Ca²⁺ signature, but achieve different structural states, only one of which can activate the enzyme. Understanding the basis for differential enzyme regulation by the plant CaMs is the first step to engineering a vertebrate CaM that will selectively alter the CaM signaling network.
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 120a
Cardiomyopathy Mutations in the Converter Domain of Human Beta-Cardiac Myosin Impairs Mechanochemistry in the Presence and Absence of Load
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 120a
Cardiomyopathy Mutations in the Converter Domain of Human Beta-Cardiac Myosin Impairs Mechanochemistry in the Presence and Absence of Load
- Open Access
- 9 January 2017
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 659
Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels
Inherited cardiomyopathies are a common form of heart disease that are caused by mutations in sarcomeric proteins with beta cardiac myosin (MYH7) being one of the most frequently affected genes. Since the discovery of the first cardiomyopathy associated mutation in beta-cardiac myosin, a major goal has been to correlate the in vitro myosin motor properties with the contractile performance of cardiac muscle. There has been substantial progress in developing assays to measure the force and velocity properties of purified cardiac muscle myosin but it is still challenging to correlate results from molecular and tissue-level experiments. Mutations that cause hypertrophic cardiomyopathy are more common than mutations that lead to dilated cardiomyopathy and are also often associated with increased isometric force and hyper-contractility. Therefore, the development of drugs designed to decrease isometric force by reducing the duty ratio (the proportion of time myosin spends bound to actin during its ATPase cycle) has been proposed for the treatment of hypertrophic cardiomyopathy. Para-Nitroblebbistatin is a small molecule drug proposed to decrease the duty ratio of class II myosins. We examined the impact of this drug on human beta cardiac myosin using purified myosin motor assays and studies of permeabilized muscle fiber mechanics. We find that with purified human beta-cardiac myosin para-Nitroblebbistatin slows actin-activated ATPase and in vitro motility without altering the ADP release rate constant. In permeabilized human myocardium, para-Nitroblebbistatin reduces isometric force, power, and calcium sensitivity while not changing shortening velocity or the rate of force development (ktr). Therefore, designing a drug that reduces the myosin duty ratio by inhibiting strong attachment to actin while not changing detachment can cause a reduction in force without changing shortening velocity or relaxation.
- 9 January 2017
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 659
Open AccessModulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels
Inherited cardiomyopathies are a common form of heart disease that are caused by mutations in sarcomeric proteins with beta cardiac myosin (MYH7) being one of the most frequently affected genes. Since the discovery of the first cardiomyopathy associated mutation in beta-cardiac myosin, a major goal has been to correlate the in vitro myosin motor properties with the contractile performance of cardiac muscle. There has been substantial progress in developing assays to measure the force and velocity properties of purified cardiac muscle myosin but it is still challenging to correlate results from molecular and tissue-level experiments. Mutations that cause hypertrophic cardiomyopathy are more common than mutations that lead to dilated cardiomyopathy and are also often associated with increased isometric force and hyper-contractility. Therefore, the development of drugs designed to decrease isometric force by reducing the duty ratio (the proportion of time myosin spends bound to actin during its ATPase cycle) has been proposed for the treatment of hypertrophic cardiomyopathy. Para-Nitroblebbistatin is a small molecule drug proposed to decrease the duty ratio of class II myosins. We examined the impact of this drug on human beta cardiac myosin using purified myosin motor assays and studies of permeabilized muscle fiber mechanics. We find that with purified human beta-cardiac myosin para-Nitroblebbistatin slows actin-activated ATPase and in vitro motility without altering the ADP release rate constant. In permeabilized human myocardium, para-Nitroblebbistatin reduces isometric force, power, and calcium sensitivity while not changing shortening velocity or the rate of force development (ktr). Therefore, designing a drug that reduces the myosin duty ratio by inhibiting strong attachment to actin while not changing detachment can cause a reduction in force without changing shortening velocity or relaxation.
- Open Access
- 21 December 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 632
Myofilament Calcium Sensitivity: Consequences of the Effective Concentration of Troponin I
Control of calcium binding to and dissociation from cardiac troponin C (TnC) is essential to healthy cardiac muscle contraction/relaxation. There are numerous aberrant post-translational modifications and mutations within a plethora of contractile, and even non-contractile, proteins that appear to imbalance this delicate relationship. The direction and extent of the resulting change in calcium sensitivity is thought to drive the heart toward one type of disease or another. There are a number of molecular mechanisms that may be responsible for the altered calcium binding properties of TnC, potentially the most significant being the ability of the regulatory domain of TnC to bind the switch peptide region of TnI. Considering TnI is essentially tethered to TnC and cannot diffuse away in the absence of calcium, we suggest that the apparent calcium binding properties of TnC are highly dependent upon an “effective concentration” of TnI available to bind TnC. Based on our previous work, TnI peptide binding studies and the calcium binding properties of chimeric TnC-TnI fusion constructs, and building upon the concept of effective concentration, we have developed a mathematical model that can simulate the steady-state and kinetic calcium binding properties of a wide assortment of disease-related and post-translational protein modifications in the isolated troponin complex and reconstituted thin filament. We predict that several TnI and TnT modifications do not alter any of the intrinsic calcium or TnI binding constants of TnC, but rather alter the ability of TnC to “find” TnI in the presence of calcium. These studies demonstrate the apparent consequences of the effective TnI concentration in modulating the calcium binding properties of TnC.
- 21 December 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 632
Open AccessMyofilament Calcium Sensitivity: Consequences of the Effective Concentration of Troponin I
Control of calcium binding to and dissociation from cardiac troponin C (TnC) is essential to healthy cardiac muscle contraction/relaxation. There are numerous aberrant post-translational modifications and mutations within a plethora of contractile, and even non-contractile, proteins that appear to imbalance this delicate relationship. The direction and extent of the resulting change in calcium sensitivity is thought to drive the heart toward one type of disease or another. There are a number of molecular mechanisms that may be responsible for the altered calcium binding properties of TnC, potentially the most significant being the ability of the regulatory domain of TnC to bind the switch peptide region of TnI. Considering TnI is essentially tethered to TnC and cannot diffuse away in the absence of calcium, we suggest that the apparent calcium binding properties of TnC are highly dependent upon an “effective concentration” of TnI available to bind TnC. Based on our previous work, TnI peptide binding studies and the calcium binding properties of chimeric TnC-TnI fusion constructs, and building upon the concept of effective concentration, we have developed a mathematical model that can simulate the steady-state and kinetic calcium binding properties of a wide assortment of disease-related and post-translational protein modifications in the isolated troponin complex and reconstituted thin filament. We predict that several TnI and TnT modifications do not alter any of the intrinsic calcium or TnI binding constants of TnC, but rather alter the ability of TnC to “find” TnI in the presence of calcium. These studies demonstrate the apparent consequences of the effective TnI concentration in modulating the calcium binding properties of TnC.
- 1 July 2016
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 601, 4-10
Designing proteins to combat disease: Cardiac troponin C as an example
- 1 July 2016
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 601, 4-10
Designing proteins to combat disease: Cardiac troponin C as an example
- Open Access
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 525a
Integration of Cardiac Troponin I Phosphorylations to Modulate Function
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 525a
Open AccessIntegration of Cardiac Troponin I Phosphorylations to Modulate Function
- Open Access
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 217a
Engineering an Anti-Arrhythmic Calmodulin
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 217a
Open AccessEngineering an Anti-Arrhythmic Calmodulin